description
Powered by Eupheria Biotech
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
ACCCTGGAGTGGAAGGTTCTCCAGTGACAGTGTCCTGTGACTGCAAAAGGGGACAAGAAAATCCCTCTTCCTCCATGGGATGGATTTAAGCTCTTGCTGTGTGTTCTACAAATGCTGTTATTGTGGGAGGAAATGCTAGGTTTTTGTGTGTGGACTGCCCAGACCTCAGCCAGGTCTTCTGGAGATGACATTTGAGGACTGATGGCCAAAGAGCATGGGGGACTGAAGCCCTGGCTGCCTCAGCGCTCTGTCTCCCAACACCAGCTGGTGTTGCAGAGGGAGGTCAACGTGAGTTTGGATCTCTTGTACGCAGATGTAATCATTCACATGTAAAAATAACCCCACCTCCCCACCCCAAAAAGGGCAAGAGCTGTGGAAAATGATTGCCAAATGAGATGGCT
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Quality Level
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Mari Gasparyan et al.
The Journal of biological chemistry, 295(34), 12188-12202 (2020-05-30)
Triple-negative breast cancer (TNBC) is an aggressive cancer subtype for which effective therapies are unavailable. TNBC has a high frequency of tumor protein p53 (Tp53/p53)- and phosphatase and tensin homolog (PTEN) deficiencies, and combined p53- and PTEN-deficiency is associated with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持